3347 — Hangzhou Tigermed Consulting Co Share Price
Last trade - 00:00- HK$29.32bn
- HK$35.19bn
- CNY7.38bn
- 59
- 30
- 57
- 45
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.52 | ||
| PEG Ratio (f) | 0.97 | ||
| EPS Growth (f) | 19.15% | ||
| Dividend Yield (f) | 1.68% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.3 | ||
| Price to Tang. Book | 1.52 | ||
| Price to Free Cashflow | 40.27 | ||
| Price to Sales | 4.01 | ||
| EV to EBITDA | 24.06 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.95% | ||
| Return on Equity | 4.55% | ||
| Operating Margin | 18.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 2,803.31 | 3,192.28 | 5,213.54 | 7,085.47 | 7,384.04 | 7,126.5 | 8,041.84 | 26.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +63.63 | +93.16 | +53.25 | -29.41 | +4.8 | -30.23 | +24.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The Company operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The Company conducts its businesses in the domestic and overseas markets.
Directors
- Xiaoping Ye CHM (58)
- Hao Wu CPR (54)
- Xiaochun Cao CFO (52)
- Zhuan Yin DGM (55)
- Jeanie Lau SEC
- Qiyu Liao IND (51)
- Bo Yang IND (49)
- Bijun Zheng IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- December 15th, 2004
- Public Since
- August 17th, 2012
- No. of Shareholders
- 65,829
- No. of Employees
- 9,701
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 864,948,570
- Address
- 15F, HANGZHOU, 310051
- Web
- https://www.tigermedgrp.com/
- Phone
- +86 57189986795
- Contact
- Xiaori Li
- Auditors
- BDO China Shu Lun Pan CPAs
Latest News for 3347
Upcoming Events for 3347
Similar to 3347
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 22:41 UTC, shares in Hangzhou Tigermed Consulting Co are trading at HK$33.90. This share price information is delayed by 15 minutes.
Shares in Hangzhou Tigermed Consulting Co last closed at HK$33.90 and the price had moved by -16.5% over the past 365 days. In terms of relative price strength the Hangzhou Tigermed Consulting Co share price has underperformed the FTSE Developed Asia Pacific Index by -21.39% over the past year.
The overall consensus recommendation for Hangzhou Tigermed Consulting Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Hangzhou Tigermed Consulting Co dividend yield is 1.8% based on the trailing twelve month period.
Last year, Hangzhou Tigermed Consulting Co paid a total dividend of CNY0.57, and it currently has a trailing dividend yield of 1.8%. We do not have any data on when Hangzhou Tigermed Consulting Co is to next pay dividends.
We do not have data on when Hangzhou Tigermed Consulting Co is to next pay dividends. The historic dividend yield on Hangzhou Tigermed Consulting Co shares is currently 1.8%.
To buy shares in Hangzhou Tigermed Consulting Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$33.90, shares in Hangzhou Tigermed Consulting Co had a market capitalisation of HK$29.32bn.
Here are the trading details for Hangzhou Tigermed Consulting Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 3347
Based on an overall assessment of its quality, value and momentum Hangzhou Tigermed Consulting Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hangzhou Tigermed Consulting Co is HK$42.20. That is 24.47% above the last closing price of HK$33.90.
Analysts covering Hangzhou Tigermed Consulting Co currently have a consensus Earnings Per Share (EPS) forecast of CNY1.65 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hangzhou Tigermed Consulting Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +2.38%.
As of the last closing price of HK$33.90, shares in Hangzhou Tigermed Consulting Co were trading +6.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hangzhou Tigermed Consulting Co PE ratio based on its reported earnings over the past 12 months is 15.52. The shares last closed at HK$33.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hangzhou Tigermed Consulting Co's management team is headed by:
- Xiaoping Ye - CHM
- Hao Wu - CPR
- Xiaochun Cao - CFO
- Zhuan Yin - DGM
- Jeanie Lau - SEC
- Qiyu Liao - IND
- Bo Yang - IND
- Bijun Zheng - IND